Literature DB >> 15374978

Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.

Archie N Tse1, Gary K Schwartz.   

Abstract

UCN-01 is a potent inhibitor of the S- and G2-M-phase cell cycle checkpoints by targeting chk1 and possibly chk2 kinases. It has been shown in some, but not all, instances that UCN-01 potentiates the cytotoxicity of DNA-damaging agents selectively in p53-defective cells. We have investigated this concept in HCT116 colon cancer cells treated with the topoisomerase I poison SN-38. SN-38 alone induced a senescence-like sustained G2 arrest without apoptosis. Sequential treatment with SN-38 followed by UCN-01 resulted in enhancement of cytotoxicity by apoptosis assay, whereas the reverse sequence or concurrent treatment did not potentiate apoptosis. Real-time visualization of HCT116 cells labeled with green fluorescent protein-histone 2B or green fluorescent protein-alpha-tubulin revealed that sequential treatment resulted in G2 checkpoint abrogation, and cells entered an aberrant mitosis despite normal assembly of bipolar spindles, resulting in either apoptosis or formation of micronucleated cells. Although p53-null cells were clearly more sensitive than parental HCT116 to undergoing checkpoint abrogation and mitotic death after sequential treatment, this was not accompanied by an increased inhibition of clonogenicity over that induced by SN-38 alone. Conversely, concurrent treatment with SN-38 and UCN-01 resulted in S-phase checkpoint override, an amplified DNA damage response including increased phosphorylation of the DNA double-strand breakage marker H2AX and augmentation of clonogenic inhibition, which was independent of p53. Thus, reported discrepancies in the pharmacology of UCN-01 and the influence of p53 status on treatment outcome appears to stem, in part, from the different schedules used, the specific checkpoints examined, and the assays used to assess cytotoxicity. Moreover, checkpoint abrogation and subsequent apoptosis induced by UCN-01 do not necessarily correlate with reproductive cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374978     DOI: 10.1158/0008-5472.CAN-04-0841

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

3.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Authors:  Jayasree S Nair; Alan L Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

4.  Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Authors:  Neil Beeharry; Eugenia Banina; James Hittle; Natalia Skobeleva; Vladimir Khazak; Sean Deacon; Mark Andrake; Brian L Egleston; Jeffrey R Peterson; Igor Astsaturov; Timothy J Yen
Journal:  Cell Cycle       Date:  2014-06-23       Impact factor: 4.534

5.  Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.

Authors:  Neil Beeharry; Jerome B Rattner; Juliane P Caviston; Tim Yen
Journal:  Cell Cycle       Date:  2013-04-24       Impact factor: 4.534

6.  p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors.

Authors:  L Petersen; G Hasvold; J Lukas; J Bartek; R G Syljuåsen
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

7.  Requirement of MTA1 in ATR-mediated DNA damage checkpoint function.

Authors:  Da-Qiang Li; Kazufumi Ohshiro; Mudassar N Khan; Rakesh Kumar
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

8.  90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Authors:  Archie N Tse; Tahir N Sheikh; Ho Alan; Ting-Chao Chou; Gary K Schwartz
Journal:  Mol Pharmacol       Date:  2008-09-26       Impact factor: 4.436

9.  Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation.

Authors:  Joshua B Stevens; Batoul Y Abdallah; Sarah M Regan; Guo Liu; Steven W Bremer; Christine J Ye; Henry H Heng
Journal:  Mol Cytogenet       Date:  2010-10-19       Impact factor: 2.009

10.  A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

Authors:  Archie N Tse; David S Klimstra; Mithat Gonen; Manish Shah; Tahir Sheikh; Rachel Sikorski; Richard Carvajal; Janet Mui; Caroll Tipian; Eileen O'Reilly; Ki Chung; Robert Maki; Robert Lefkowitz; Karen Brown; Katia Manova-Todorova; Nian Wu; Merrill J Egorin; David Kelsen; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.